Certified by Founder
Lodge
Congruence Therapeutics
start up
Canada
- Montreal, Quebec
- 07/03/2023
- Series A
- $65,000,000
Congruence Therapeutics is a drug discovery company that is uniquely harnessing the power of innovative fields such as protein dynamics, biophysics, machine learning and computational chemistry. Our ground-breaking discovery engine, Revenir, sees proteins in ways others have been unable to see - in their full dynamic state.
- Industry Biotechnology Research
- Website https://congruencetx.com/
- LinkedIn https://www.linkedin.com/company/congruencetx/people/
Related People
Clarissa DesjardinsFounder
Canada -
Montreal, Quebec,
Experienced biotechnology executive and founder of three successful biotechnology companies. Founded Clementia Pharmaceuticals and led it to Phase 3 human clinical trials for fibrodysplasia ossificans progressiva (FOP), a disease of abnormal new bone formation, until its acquisition by Ipsen for $1.3 billion dollars in 2019.
Forage | $40,000,000 | (Jun 5, 2026)
InCharge Energy | $46,000,000 | (Jun 5, 2026)
Oak Hill Bio | $32,500,000 | (Jun 5, 2026)
ZutaCore | $100,000,000 | (Jun 5, 2026)
Terra AI | $20,000,000 | (Jun 5, 2026)
Town | $55,000,000 | (Jun 5, 2026)
Lassie | $35,000,000 | (Jun 5, 2026)
OFFROAD | $7,000,000 | (Jun 5, 2026)
Shifters | $10,200,000 | (Jun 5, 2026)
Quobly | $133,545,475 | (Jun 5, 2026)
Scispot | $8,000,000 | (Jun 5, 2026)
Scotch | $20,000,000 | (Jun 5, 2026)